These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38029742)

  • 1. Enhanced neutralization of SARS-CoV-2 variant BA.2.86 and XBB sub-lineages by a tetravalent COVID-19 vaccine booster.
    Wang X; Jiang S; Ma W; Li X; Wei K; Xie F; Zhao C; Zhao X; Wang S; Li C; Qiao R; Cui Y; Chen Y; Li J; Cai G; Liu C; Yu J; Li J; Hu Z; Zhang W; Jiang S; Li M; Zhang Y; Wang P
    Cell Host Microbe; 2024 Jan; 32(1):25-34.e5. PubMed ID: 38029742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination
    Wang H; Xue Q; Zhang H; Yuan G; Wang X; Sheng K; Li C; Cai J; Sun Y; Zhao J; Lu J; Fang S; Yang Y; Zhang Y; Huang Y; Wang J; Xu JH; Jiang MX; Wang X; Shen L; Liu Y; Liu Q; Zhang Q; Wang S; Wang P; Qiu C; Ai J; Zhang W
    Emerg Microbes Infect; 2023 Dec; 12(2):2249121. PubMed ID: 37668156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralization of SARS-CoV-2 Omicron XBB.1.5 and JN.1 variants after COVID-19 booster-vaccination and infection.
    Springer DN; Camp JV; Aberle SW; Deutsch J; Lammel O; Weseslindtner L; Stiasny K; Aberle JH
    J Med Virol; 2024 Jul; 96(7):e29801. PubMed ID: 38988204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants.
    Wang R; Huang H; Yu C; Sun C; Ma J; Kong D; Lin Y; Zhao D; Zhou S; Lu J; Cao S; Zhang Y; Luo C; Li X; Wang Y; Xie L
    Sci China Life Sci; 2023 Aug; 66(8):1818-1830. PubMed ID: 36598621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1.
    Hu Y; Zou J; Kurhade C; Deng X; Chang HC; Kim DK; Shi PY; Ren P; Xie X
    Emerg Microbes Infect; 2023 Dec; 12(2):2271089. PubMed ID: 37824708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1.
    Liu S; Liang Z; Nie J; Gao WB; Li X; Zhang L; Yu Y; Wang Y; Huang W
    Emerg Microbes Infect; 2023 Dec; 12(2):2225638. PubMed ID: 37313604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.
    Favresse J; Gillot C; Cabo J; David C; Dogné JM; Douxfils J
    Int J Infect Dis; 2024 Jun; 143():107028. PubMed ID: 38583825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low neutralization of SARS-CoV-2 Omicron BA.5.2.48 and XBB.1 sub-variants in response to breakthrough infection by booster.
    Li J; Gong L; Li J; Gong Z; Wang X; Yan H; Zhang Y; Mao H; Chen K
    Vaccine; 2024 Jul; 42(18):3751-3755. PubMed ID: 38714449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Previous exposure to Spike-providing parental strains confers neutralizing immunity to XBB lineage and other SARS-CoV-2 recombinants in the context of vaccination.
    Suryawanshi RK; Taha TY; McCavitt-Malvido M; Silva I; Khalid MM; Syed AM; Chen IP; Saldhi P; Sreekumar B; Montano M; Foresythe K; Tabata T; Kumar GR; Sotomayor-Gonzalez A; Servellita V; Gliwa A; Nguyen J; Kojima N; Arellanor T; Bussanich A; Hess V; Shacreaw M; Lopez L; Brobeck M; Turner F; Wang Y; Ghazarian S; Davis G; Rodriguez D; Doudna J; Spraggon L; Chiu CY; Ott M
    Emerg Microbes Infect; 2023 Dec; 12(2):2270071. PubMed ID: 37869789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low neutralization of SARS-CoV-2 Omicron BA.5.2.48, BF.7.14, XBB.1 subvariants by homologous or heterologous booster.
    Li J; Mao H; Song W; Chen Y; Feng Y; Li J; Su L; Li X; Shi W; Wu Y; Huang C; Zhang Y; Chen K
    J Med Virol; 2023 Dec; 95(12):e29306. PubMed ID: 38084772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children.
    Bellusci L; Grubbs G; Sait S; Yonker LM; Randolph AG; Novak T; Kobayashi T; ; Khurana S
    Nat Commun; 2023 Dec; 14(1):7952. PubMed ID: 38040697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategy to develop broadly effective multivalent COVID-19 vaccines against emerging variants based on Ad5/35 platform.
    Chang S; Shin KS; Park B; Park S; Shin J; Park H; Jung IK; Kim JH; Bae SE; Kim JO; Baek SH; Kim G; Hong JJ; Seo H; Volz E; Kang CY
    Proc Natl Acad Sci U S A; 2024 Mar; 121(10):e2313681121. PubMed ID: 38408238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages.
    Guo L; Zhang Q; Zhong J; Chen L; Jiang W; Huang T; Li Y; Zhang Y; Xu L; Wang X; Xiao Y; Wang Y; Dong X; Dong T; Peng Y; Zhang B; Xie Y; Gao H; Shen Z; Ren L; Cheng T; Wang J
    Emerg Microbes Infect; 2023 Dec; 12(1):2202263. PubMed ID: 37037791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection.
    Zhu KL; Jiang XL; Zhan BD; Wang XJ; Xia X; Cao GP; Sun WK; Huang PX; Zhang JZ; Gao YL; Dai EH; Gao HX; Ma MJ
    Cell Rep; 2023 Feb; 42(2):112075. PubMed ID: 36774551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated Omicron infection dampens immune imprinting from previous vaccination and induces broad neutralizing antibodies against Omicron sub-variants.
    Gong X; Peng L; Wang F; Liu J; Tang Y; Peng Y; Niu S; Yin J; Guo L; Lu H; Liu Y; Yang Y
    J Infect; 2024 Aug; 89(2):106208. PubMed ID: 38908522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
    Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralization sensitivity of SARS-CoV-2 Omicron variants FL.1 and GE.1 by therapeutic antibodies and XBB sera.
    Lee J; Naoe Y; Bang U; Nakagama Y; Saito A; Kido Y; Hotta A
    Virology; 2024 Jul; 595():110067. PubMed ID: 38653156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster.
    Kurhade C; Zou J; Xia H; Liu M; Chang HC; Ren P; Xie X; Shi PY
    Nat Med; 2023 Feb; 29(2):344-347. PubMed ID: 36473500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of immune response to SARS-CoV-2 Omicron sublineages six months after different vaccination regimens in Italy.
    Trombetta CM; Marchi S; Leonardi M; Coppola C; Benincasa L; Marotta MG; Buonvino N; Maes P; Stufano A; Pontrelli D; Vasinioti VI; Manenti A; Camero M; Montomoli E; Decaro N; Lovreglio P
    Acta Trop; 2023 Dec; 248():107042. PubMed ID: 37863379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants.
    Patel N; Trost JF; Guebre-Xabier M; Zhou H; Norton J; Jiang D; Cai Z; Zhu M; Marchese AM; Greene AM; Mallory RM; Kalkeri R; Dubovsky F; Smith G
    Sci Rep; 2023 Nov; 13(1):19176. PubMed ID: 37932354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.